AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PARADIGM BIOPHARMACEUTICALS

0.305

-0.005-1.61%

Volume:787.40K

Turnover:242.25K

Market Cap:132.21M

PE:-5.11

High:0.315

Open:0.315

Low:0.302

Close:0.310

52wk High:0.660

52wk Low:0.255

Shares:433.46M

Float Shares:353.07M

Volume Ratio:1.67

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.060

EPS(LYR):-0.060

ROE:-81.66%

ROA:-55.11%

PB:6.24

PE(LYR):-5.11

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-5.95%

Capital Flow

Inflow:

Outflow:

News

Paradigm Says Study Evaluating Lead Product in Canine Arthritis Show Sustained Reductions in Chronic Pain

MT Newswires Live

BRIEF-Paradigm Biopharmaceuticals Signs Binding Veterinary Licensing & Supply Agreement

Paradigm Biopharmaceuticals Secures Binding Term Sheet With Veterinary Pharmaceutical Company; Shares Up 3%

MT Newswires Live

Paradigm Biopharmaceuticals Ltd - Signs Binding Veterinary Licensing & Supply Agreement for Oral PPS + Cox-2 Inhibitor Combination

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PAR.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.305,"timestamp":1770774718135,"preClose":0.31,"halted":0,"volume":787398,"delay":0,"changeRate":-0.01612903225806453,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":433460088,"eps":-0.059699,"marketStatus":"Trading","change":-0.005,"latestTime":"02-11 12:53:28 AEDT","open":0.315,"high":0.315,"low":0.302,"amount":242252,"amplitude":0.041935,"askPrice":0.31,"askSize":188367,"bidPrice":0.305,"bidSize":97000,"shortable":3,"etf":0,"ttmEps":-0.059699,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770786000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.31,"openAndCloseTimeList":[[1770764400000,1770786000000]],"volumeRatio":1.673312,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-55.11%","roe":"-81.66%","lyrEps":-0.059684,"volumeRatio":1.673312,"shares":433460088,"dividePrice":0,"high":0.315,"amplitude":0.041935,"preClose":0.31,"low":0.302,"week52Low":0.255,"pbRate":"6.24","psRate":"7916.49","week52High":0.66,"institutionHeld":0,"latestPrice":0.305,"committee":-0.320174,"eps":-0.059699,"divideRate":0,"volume":787398,"delay":0,"ttmEps":-0.059699,"open":0.315,"prevYearClose":0.34,"prevWeekClose":0.29,"prevMonthClose":0.305,"prevQuarterClose":0.34,"fiveDayClose":0.3,"twentyDayClose":0.345,"sixtyDayClose":0.365,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610187608","title":"Paradigm Says Study Evaluating Lead Product in Canine Arthritis Show Sustained  Reductions in Chronic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2610187608","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610187608?lang=en_us&edition=fundamental","pubTime":"2026-02-11 08:30","pubTimestamp":1770769806,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said a study of its lead product, pentosan polysulfate sodium , in canine osteoarthritis showed sustained reductions in chronic pain and normalization of gait symmetry through 26 weeks, compared with placebo, according to a Wednesday filing with the Australian bourse.The study assesses the durability and potential disease-modifying effects of a six-week course of PPS in dogs with naturally occurring osteoarthritis of the stifle and/or elbow joints, the filing said.Following the treatment, magnetic resonance imaging and serum biomarker findings were consistent with slowed cartilage degradation and altered bone and cartilage turnover, the filing said.The study also provides a compressed analogue of longer-term human outcomes, the filing added.Shares of the company fell 1% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7016","BK7503","PPS","PAR.AU","PPS.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2610350119","title":"BRIEF-Paradigm Biopharmaceuticals Signs Binding Veterinary Licensing & Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2610350119","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610350119?lang=en_us&edition=fundamental","pubTime":"2026-02-09 09:42","pubTimestamp":1770601357,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Signs Binding Veterinary Licensing & Supply AgreementFeb 9  - Paradigm Biopharmaceuticals Ltd PAR.AX:SIGNS BINDING VETERINARY LICENSING & SUPPLY AGREEMENT FOR ORAL PPS + COX-2 INHIBITOR COMBINATIONCO ELIGIBLE TO RECEIVE UP TO A$1 MILLION FROM AVET IN DEVELOPMENT MILESTONESFurther company coverage: PAR.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nFWN3Z21W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2610506213","title":"Paradigm Biopharmaceuticals Secures Binding Term Sheet With Veterinary Pharmaceutical Company; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610506213","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610506213?lang=en_us&edition=fundamental","pubTime":"2026-02-09 08:42","pubTimestamp":1770597732,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  secured a binding term sheet with AVet Health for the co-development and licensing of an oral combination therapy for the treatment of osteoarthritis in companion animals, according to a Monday filing with the Australian bourse.AVet Health will hold exclusive rights in Australia and New Zealand under the deal, with a first right of refusal for all other markets excluding the US, with the company eligible to receive up to AU$1 million in development milestones, the filing said.Once the licensing agreement is finalized, the company will receive tiered royalties of up to 20% on net sales and run for 15 years post-registration with the Australian Pesticides and Veterinary Medicines Authority, per the filing.Paradigm Biopharmaceuticals shares rose 3% in morning trade on Monday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2610508204","title":"Paradigm Biopharmaceuticals Ltd - Signs Binding Veterinary Licensing & Supply Agreement for Oral PPS + Cox-2 Inhibitor Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2610508204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610508204?lang=en_us&edition=fundamental","pubTime":"2026-02-09 06:08","pubTimestamp":1770588502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nFWN3Z21W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7067","BK7508"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PAR.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.059536}]}}